NCT05967819

Brief Summary

The goal of this clinical trial is to determine how changes in exercise and psychosocial stress may influence the risk of menstrual cycle irregularities in female runners and cyclists. The main questions it aims to answer are:

  • Does the implementation of exercise or psychosocial stress effect circulating reproductive hormones (i.e., estradiol, progesterone, luteinizing hormone) and menstrual cycle length?
  • Is there an additive effect of combined exercise and psychosocial on circulating reproductive hormones (i.e., estradiol, progesterone, luteinizing hormone) and menstrual cycle length? Participants will be asked to do the following over the \~3 month enrollment period:
  • attend a laboratory visit at the beginning and end of the study to have their resting metabolic rate, aerobic fitness, and body composition tested
  • monitor their menstrual cycle length, daily perceived stress levels, physical activity, and diet each month
  • provide several urine and saliva samples each month
  • either maintain their usual physical activity and lifestyle habits (control group), increase the duration of their weekly running or cycling mileage by 30% (exercise stress group), complete cognitive function tasks designed to be stressful (psychosocial stress group), or increase the duration of their weekly running or cycling mileage by 30% and complete cognitive function tasks designed to be stressful (exercise + psychosocial stress group) during the final month of enrollment. Researchers will compare control, exercise stress, psychosocial stress, and exercise + psychosocial stress groups to see if there is an effect on circulating reproductive hormones (i.e., estradiol, progesterone, luteinizing hormone) and menstrual cycle length.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
54

participants targeted

Target at P25-P50 for not_applicable

Timeline
4mo left

Started Aug 2023

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress90%
Aug 2023Aug 2026

First Submitted

Initial submission to the registry

July 21, 2023

Completed
11 days until next milestone

First Posted

Study publicly available on registry

August 1, 2023

Completed
8 days until next milestone

Study Start

First participant enrolled

August 9, 2023

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 30, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 30, 2026

Last Updated

January 8, 2026

Status Verified

January 1, 2026

Enrollment Period

3.1 years

First QC Date

July 21, 2023

Last Update Submit

January 5, 2026

Conditions

Keywords

functional hypothalamic amenorrheamenstrual cyclefemale athlete

Outcome Measures

Primary Outcomes (4)

  • Urinary estrone-3-glucuronide (E3G)

    ng/mL

    3 months

  • Urinary pregnanediol glucuronide (PdG)

    ug/mL

    3 months

  • Urinary luteinizing hormone (LH)

    MIU/mL

    3 months

  • Menstrual cycle length

    days

    3 months

Study Arms (4)

Control

NO INTERVENTION

Participants will be asked to maintain their usual physical activity and lifestyle habits.

Exercise Stress

EXPERIMENTAL

The duration of participant's weekly running or cycling mileage will be increased by 30% while intensity is maintained.

Behavioral: Exercise Stress

Psychosocial Stress

EXPERIMENTAL

Participants will be asked to complete cognitive function tasks designed to be stressful while maintaining their usual physical activity habits.

Behavioral: Psychosocial Stress

Exercise + Psychosocial Stress

EXPERIMENTAL

Participants will be asked to complete cognitive function tasks designed to be stressful while the duration of their weekly running or cycling mileage is increased by 30% and intensity maintained.

Behavioral: Exercise StressBehavioral: Psychosocial Stress

Interventions

Exercise StressBEHAVIORAL

Increased exercise volume

Exercise + Psychosocial StressExercise Stress

cognitive tasks

Exercise + Psychosocial StressPsychosocial Stress

Eligibility Criteria

Age18 Years - 35 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • participates in structured running or cycling exercise for at least 30 minutes on 4 days per week or more
  • have regular periods every 21 to 35 days
  • have not used hormonal contraceptives for at least the past 6 months
  • are not currently or trying to become pregnant or are breastfeeding, and have not been pregnant or breastfeeding for the past 12 months
  • have never been diagnosed with a menstrual cycle disorder (e.g., menorrhagia, amenorrhea, dysmenorrhea, polycystic ovary syndrome \[PCOS\], endometriosis, premenstrual dysphoric disorder \[PMDD\], menstrual migraines, ovarian cancer, ovarian insufficiency, uterine or endometrial cancer)
  • have never been diagnosed with a metabolic disease (e.g., hypothyroidism, hyperthyroidism, Cushing disease, Addison's disease, diabetes)

You may not qualify if:

  • missing \> 4 consecutive days of aerobic exercise (i.e., running, cycling, cross training) if assigned to the exercise intervention groups
  • they indicate they "Could not participate at all due to a health problem" or have had to modify their exercise training, felt their injury, illness, or other health problem has affected their exercise performance, or experienced symptoms/ health complaints greater than "To a minor extent" on the Oslo Sports Trauma Research Center Questionnaire (exercise training intervention group)
  • demonstrate clinical low energy availability as defined as energy availability \<30 Kcal/kg fat free mass in the first two months of at-home monitoring
  • report menstrual cycle lengths \<21 days or \>35 days in the first two months of at-home monitoring
  • do not demonstrate an anticipated rise in progesterone levels during the latter half of their cycle and luteinizing hormone levels at mid-cycle compared to tests taken during the first few days after menses in the first two months of at-home monitoring
  • begin taking a hormonal contraceptive
  • become pregnant
  • are diagnosed with a menstrual cycle disorder (e.g., menorrhagia, amenorrhea, dysmenorrhea, polycystic ovary syndrome \[PCOS\], endometriosis, premenstrual dysphoric disorder \[PMDD\], menstrual migraines, ovarian cancer, ovarian insufficiency, uterine or endometrial cancer)
  • are diagnosed with a metabolic disease (e.g., hypothyroidism, hyperthyroidism, Cushing disease, Addison's disease, diabetes), 10) are diagnosed with a major cardiovascular disease, respiratory disease, or musculoskeletal injury
  • are unable to follow instructions for any of the procedures

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Colorado Colorado Springs

Colorado Springs, Colorado, 80918, United States

RECRUITING

MeSH Terms

Interventions

Exercise Test

Intervention Hierarchy (Ancestors)

Heart Function TestsDiagnostic Techniques, CardiovascularDiagnostic Techniques and ProceduresDiagnosisRespiratory Function TestsDiagnostic Techniques, Respiratory SystemErgometryInvestigative Techniques

Central Study Contacts

Marissa Baranauskas, PhD

CONTACT

Kristen Rudd, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
FACTORIAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

July 21, 2023

First Posted

August 1, 2023

Study Start

August 9, 2023

Primary Completion (Estimated)

August 30, 2026

Study Completion (Estimated)

August 30, 2026

Last Updated

January 8, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will not share

Locations